PURE Bioscience (OTCMKTS:PURE) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.

Shares of PURE Bioscience (PURE) traded down $0.06 during mid-day trading on Friday, reaching $1.00. 86,939 shares of the company’s stock traded hands, compared to its average volume of 37,639. PURE Bioscience has a twelve month low of $0.75 and a twelve month high of $1.36.

TRADEMARK VIOLATION WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/10/pure-bioscience-pure-lowered-to-sell-at-valuengine.html.

PURE Bioscience Company Profile

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.